Wize Pharma 

Wize Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the treatment of ophthalmic disorders. It has in-license rights to purchase, market, sell, and distribute LO2A for the treatment of dry eye syndrome (DES) and other ophthalmological illnesses, including Conjunctivochalasis and Sjögren's syndrome (Sjögren's) in the United States and other territories. The company is also conducting a Phase IV study for LO2A for DES in patients with Sjögren's. The company was formerly known as Star Night Technologies Ltd. and changed its name to Wize Pharma, Inc. in July 2015. Wize Pharma, Inc. was founded in 1982 and is headquartered in Hod Hasharon, Israel.